生物试剂
>
生化试剂
>
信号通路
> MYCMI-6 促销
加入收藏 取消收藏

MYCMI-6 促销  ≥95%

促销价¥{{model.attbuying.price}}

市场价¥0.00

累计销量0 累计评价0 人评论

别称 {{model.alias}}
中文名称 {{model.name}}
英文名称 {{model.enname}}
品牌 {{model.brand}}
CAS {{model.cas}}
分子式
分子量 {{model.molecularweight}}
MDL {{model.mdl}}
货号 {{model.procode}}
数量

+ -

件 库存{{model.attbuying.number}}件
立即购买 加入购物车 下载说明书

看了又看
包装规格：1mg 5mg 10mg 50mg in glass bottle
溶解性：溶于DMSO（2 mg/mL 超声）
产品描述：基本信息 产品编号：M10787 产品名称：MYCMI-6 CAS: 681282-09-7   储存条件 粉末 -20℃ 四年     分子式： C20H19N7O 溶于液体 -80℃ 六个月 分子量 373.41 -20℃ 一个月 化学名：      Solubility (25°C)   体外 DMSO   Ethanol   Water   体内（现配现用）     ＜1mg/ml表示微溶或不溶。 普西唐提供的所有化合物浓度为内部测试所得，实际溶液度可能与公布值有所偏差，属于正常的批间细微差异现象。 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；⼀旦配成溶液，请分装保存，避免反复冻融造成的产品失效。   制备储备液   浓度   溶液体积 质量   1mg   5mg   10mg 1mM 2.6780mL 13.3901mL 26.7802mL 5mM 0.5356mL 2.6780mL 5.3560mL   生物活性 产品描述 一种有效的选择性内源性 MYC:MAX 蛋白相互作用抑制剂。 靶点/IC50 c-Myc Apoptosis   体外研究 MYCMI-6 (NSC354961) (6.25μM; 48 hours) selectively suppresses MYC-driven tumor cell growth with high efficacy.MYCMI-6 significantly inhibits growth of Burkitt’s lymphoma cells (Mutu,Daudi and ST486) - another classical example of a MYC-driven tumor, having translocations of MYC to one of the immunoglobulin loci - in a dose-dependent manner with an average GI50 of 0.5μM.Treatment of MCF7 cells with the MYCMI-6 for 24 hours significantly decreased MYC:MAX isPLA signals to 7%. Titration showed an IC50 for inhibition of MYC:MAX of less than 1.5μM for MYCMI-6 by isPLA. MYCMI-6 inhibits the MYC:MAX heterodimer formation with an IC50 of 3.8μM.MYCMI-6 efficiently inhibits anchorage-independent growth of MYCN-amplified neuroblastoma cells with GI50 values of <0.4μM.Cell Viability Assay Cell Line: MYCN-amplified neuroblastoma cells (IMR-32, Kelly and SK-N-DZ), MYCN-non-amplified neuroblastoma cells (SK-N-F1, SK-N-AS and SK-N-RA) Concentration: 6.25μM Incubation Time: 48 hours Result: Result: Reduced growth of the MYCN-amplified cell lines significantly stronger than the MYCN-nonamplified cell lines. 体内研究 MYCMI-6 (20mg/kg; i.p.; daily for 1-2 weeks) induces massive apoptosis and reduces tumor cell proliferation, tumor microvasculature density and MYC:MAX interaction in a MYC-dependent xenograft tumor model. Animal Model: 6-8 weeks old athymic nude mice (bearing MYCN-amplified SK-N-DZ neuroblastoma cells) Dosage: 20 mg/kg body weight Administration: I.p.; daily for 1-2 weeks Result: A dramatic increase in the extension of apoptotic areas in the tumors and a significant increase in non-proliferative areas as determined by Ki67 staining in tumors.
保存条件：-20℃

猜你喜欢